The PALMARES-2 trial reveals that abemaciclib and ribociclib outperform palbociclib in real-world progression-free survival for advanced breast cancer patients.

Panelist discusses how efficacy and safety data from trials like ELEVATE-TN and CLL14 inform treatment decisions, noting that while both regimens are effective, patients with 17p deletion tend to ...

The FDA approves SIR-Spheres Y-90 microspheres for treating unresectable hepatocellular carcinoma, showcasing impressive ...

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and ...

Marwan G. Fakih, MD, discusses the top takeaways from using combination treatment in metastatic colorectal cancer.